Generated by AI
Korro Bio Inc. is a biopharmaceutical company focused on developing genetic medicines based on RNA editing. The company uses its proprietary OPERA platform, short for oligonucleotide promoted editing of RNA, to create therapies that make precise changes at the RNA level rather than permanently altering DNA. Its current pipeline centers on treatments for rare and highly prevalent diseases, with lead programs targeting liver-directed and other genetically defined conditions such as hyperammonemia, alpha-1 antitrypsin deficiency, and additional disorders with high unmet medical need. Korro Bio Inc. develops its candidates through discovery, preclinical, and clinical-stage research, combining RNA biology, oligonucleotide chemistry, and disease-specific design to generate differentiated therapeutic options. The company is headquartered in Cambridge, Massachusetts, and its work positions it within the growing field of next-generation genetic medicine.
Website60 First Street
Cambridge, MA, 02141
United States
The latest articles about KRRO.
Summary of Oct 22's posts. Generated by AI.
Summary of Mar 13's posts. Generated by AI.
No summary yet.
Summary of Oct 22's posts. Generated by AI.
Investors talking about KRRO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.